Skip to main content

Main menu

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI

User menu

  • Subscribe
  • My alerts
  • Log in
  • My Cart

Search

  • Advanced search
Journal of Nuclear Medicine
  • SNMMI
    • JNM
    • JNMT
    • SNMMI Journals
    • SNMMI
  • Subscribe
  • My alerts
  • Log in
  • My Cart
Journal of Nuclear Medicine

Advanced Search

  • Home
  • Content
    • Current
    • Ahead of print
    • Past Issues
    • JNM Supplement
    • SNMMI Annual Meeting Abstracts
  • Subscriptions
    • Subscribers
    • Institutional and Non-member
    • Rates
    • Corporate & Special Sales
    • Journal Claims
  • Authors
    • Submit to JNM
    • Information for Authors
    • Assignment of Copyright
    • AQARA requirements
  • Info
    • Permissions
    • Advertisers
    • Continuing Education
  • About
    • About Us
    • Editorial Board
    • Contact Information
  • More
    • Alerts
    • Feedback
    • Help
    • SNMMI Journals
  • Follow JNM on Twitter
  • Visit JNM on Facebook
  • Join JNM on LinkedIn
  • Subscribe to our RSS feeds
Meeting ReportOral - PhysicianPharm

The comparison of therapeutic effect between [211At]NaAt and [131I]NaI: preclinical study using mice xenograft model of differentiated thyroid cancer

Yuwei Liu, Tadashi Watabe, Kazuko Kaneda-Nakashima, Kazuhiro Ooe, Yoshifumi Shirakami, Atsushi Toyoshima, Eku Shimosegawa, Takashi Nakano, Atsushi Shinohara and Jun Hatazawa
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 98;
Yuwei Liu
1department of nuclear medicine and tracer kinetics,osaka university Osaka Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Tadashi Watabe
2Osaka University Graduate School of Medicine Suita Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kazuko Kaneda-Nakashima
3Osaka University Toyonaka Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kazuhiro Ooe
4Osaka University Suita Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yoshifumi Shirakami
4Osaka University Suita Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Atsushi Toyoshima
5Osaka University Toyonaka, Osaka Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eku Shimosegawa
2Osaka University Graduate School of Medicine Suita Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Takashi Nakano
6Institute for Radiation Sciences, Osaka University Suita, Japan Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Atsushi Shinohara
7Graduate School of Science, Osaka Uiversity Osaka Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jun Hatazawa
8Institute for Radiation Sciences, Osaka University Suita, Osaka Japan
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Figures & Data
  • Info & Metrics
Loading

Abstract

98

Purpose: Astatine(211At), an alpha-emitter with similar chemical properties to iodine, is expected to have a better therapeutic effect compared to 131I (beta-emitter). In the previous study, we revealed the dose-dependent therapeutic effect of 211At-NaAt solution by K1-NIS xenograft mice. In this study, we aimed to prove the better therapeutic effect of 211At-NaAt than 131I-NaI in differentiated thyroid cancer model.

Methods: Colony assay and DNA double-strand break (DSB) assay were performed using K1-NIS (NIS-expressing human papillary thyroid cancer) cells with different activities of 131I-NaI and 211At-NaAt solutions. Biodistribution of 131I-NaI and 211At-NaAt were measured in K1-NIS xenograft mice (n=3 for each group) at 24 hours after administration. 1MBq (n=4), 4MBq (n=4) and 8MBq (twice administration of 4MBq, n=4) of 131I-NaI solution and 0.4MBq of 211At-NaAt solution (n=9) were injected to each group of K1-NIS xenograft mice. Tumor size were followed and compared.

Results: In in-vitro assay, 211At-NaAt significantly inhibited the colony formation and induced more DSBs in K1-NIS cells compared to 131I-NaI. The uptake in the tumor was higher in mice administrated with 211At-NaAt solution at 24 hours after injection. 131I-NaI solution showed tumor growth inhibition in a dose-dependent manner in the tumor xenograft model of K1-NIS. However, the effect on tumor shrinkage was minimal in 131I-NaI. 211At-NaAt solution showed better tumor-suppressive effect with longer interval for regrowth than 131I-NaI solution.

Conclusions: The 211At-NaAt induced more DSBs with better tumor-suppression effect compared to 131I-NaI in vitro and in vivo, suggesting the application of 211At-NaAt therapy for differentiated thyroid cancer instead of 131I-NaI. Figure 1. The comparison of DSB generated in K1-NIS cells between 211At-NaAt and 131I-NaI group, are expressed as the ratio of DSB in RI-treated group to control group. Figure.2. Change in the relative tumor size after administration of 131I-NaI solution. Figure 3. The comparison of relative tumor size of K1-NIS xenograft mice administrated with 4MBq 131I-NaI solution and 0.4MBq 211At-NaAt solution.

Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Figure
  • Download figure
  • Open in new tab
  • Download powerpoint
Previous
Back to top

In this issue

Journal of Nuclear Medicine
Vol. 62, Issue supplement 1
May 1, 2021
  • Table of Contents
  • Index by author
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Journal of Nuclear Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The comparison of therapeutic effect between [211At]NaAt and [131I]NaI: preclinical study using mice xenograft model of differentiated thyroid cancer
(Your Name) has sent you a message from Journal of Nuclear Medicine
(Your Name) thought you would like to see the Journal of Nuclear Medicine web site.
Citation Tools
The comparison of therapeutic effect between [211At]NaAt and [131I]NaI: preclinical study using mice xenograft model of differentiated thyroid cancer
Yuwei Liu, Tadashi Watabe, Kazuko Kaneda-Nakashima, Kazuhiro Ooe, Yoshifumi Shirakami, Atsushi Toyoshima, Eku Shimosegawa, Takashi Nakano, Atsushi Shinohara, Jun Hatazawa
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 98;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
The comparison of therapeutic effect between [211At]NaAt and [131I]NaI: preclinical study using mice xenograft model of differentiated thyroid cancer
Yuwei Liu, Tadashi Watabe, Kazuko Kaneda-Nakashima, Kazuhiro Ooe, Yoshifumi Shirakami, Atsushi Toyoshima, Eku Shimosegawa, Takashi Nakano, Atsushi Shinohara, Jun Hatazawa
Journal of Nuclear Medicine May 2021, 62 (supplement 1) 98;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One
Bookmark this article

Jump to section

  • Article
  • Figures & Data
  • Info & Metrics

Related Articles

  • No related articles found.
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

Oral - PhysicianPharm

  • Safety and efficacy of radioligand therapy with 177lutetium-PSMA-617 within 3 months after 223Radium-dichloride
  • Usefulness of99mTc SESTAMIBI Scintigraphy in Persistent Hyperparathyroidism after Kidney Transplant
  • Toll-like receptor 5 in triple-negative breast cancer: a novel reporter for tumor progression
Show more Oral - PhysicianPharm

Oncology (Science), Basic and Translation: Therapy

  • PET Imaging of Upregulated VLA-4 in a Novel Mouse Model of BRAFV600E Melanoma
  • Combination of IGF-1R targeted alpha therapy with Olaparib results in synergistic efficacy against colorectal and lung cancer xenografts.
  • High-throughput screening and bioinformatics analysis of 2,000 177Lu-PSMA and Radiotherapy + drug combinations
Show more Oncology (Science), Basic and Translation: Therapy

Similar Articles

SNMMI

© 2022 Journal of Nuclear Medicine

Powered by HighWire